



Protein degraded.
Disease targeted.
Lives transformed.

May 2024



Forward-looking Statements and Intellectual Property

Forward-looking Statements

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.’s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The forward-looking statements included in this presentation are subject to a variety of risks and uncertainties, including those set forth in our most recent and future filings with the Securities and Exchange Commission. Our actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.


Intellectual Property

C4 Therapeutics, Inc. owns various registered and unregistered trademarks and service marks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are referred to without the symbols ®, SM and TM, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights to.

C4T is a Recognized Leader in Delivering on the Promise of Targeted Protein Degradation

Our Mission

To deliver on the promise of targeted protein degradation science to create a new generation of medicines that transform patients' lives



WORLD-CLASS DEGRADER PLATFORM

Robust patent portfolio of novel cereblon binders; Demonstrated ability to design **orally bioavailable, catalytically efficient degraders**

RIGOROUS TARGET SELECTION

Focus on targets with a **clear degrader rationale**


BROAD DEGRADER APPROACH

MonoDAC and **BiDAC** degraders, as well as **degrader-antibody conjugates**

CLINICAL PIPELINE

Oncology degraders against targets of high unmet need


We Have Designed and Advanced Degraders into the Clinic Across a Range of Target Classes, Resulting in Robust Target Degradation




Interrogated Diverse Target Classes



Attained IND Clearance



Achieved Desirable Drug-like Properties



Degraded Target as Predicted



Discovered degraders and advanced **4 INDs** against a transcription factor, a chromatin modifier, and two kinases



To date, we have evaluated **3 programs** in the clinic¹, with each demonstrating robust target degradation in patients

¹. Evaluated three programs in the clinic as of 1/9/2024 Investigational New Drug Application (IND)

Prioritized Pipeline to Deliver Near-Term Value

Program	Target	Indications	Discovery	Preclinical	Early phase development	Late phase development	Rights
Cemsidomide (CFT7455)	IKZF1/3	Multiple Myeloma & Non-Hodgkin's Lymphoma					
CFT1946	BRAF V600X	V600X Mutant Cancers					
CFT8919¹	EGFR L858R	Non-Small Cell Lung Cancers					

Undisclosed Discovery Stage Programs	Various Cancers						
Undisclosed Collaboration Programs	Autoimmune & Cancer	2 targets					
	Autoimmune & Neurological	2 targets					
	Cancer	1 target					
	Cancer	2 targets					Merck KGaA Darmstadt, Germany

1. License and Collaboration Agreement with Beta Pharmaceuticals for development and commercialization in Greater China

2024 Milestones: Advancing High-potential Programs

Multiple Value Inflection Points over Next 12 Months with Sufficient Runway (into 2027¹) Beyond These Milestones

Cemsidomide (CFT7455) IKZF1/3

- **2H 2024:** Present updated data from Phase 1 dose escalation +dex trial in R/R MM
- **2H 2024:** Present data from Phase 1 dose escalation monotherapy trial in R/R NHL
- **By YE 2024:** Complete Phase 1 dose exploration in R/R MM and R/R NHL

CFT1946 BRAF V600X

- ✓ **2Q 2024:** Present preclinical data demonstrating differentiated activity in BRAF V600X melanoma, CRC, NSCLC, and brain metastasis models at AACR
- **2H 2024:** Present data from Phase 1 dose escalation trial in melanoma, CRC, NSCLC, and other BRAF V600X cancers

CFT8919 EGFR L858R

- **2024:** Support trial start-up activities related to Betta's Phase 1 dose escalation trial in China

Discovery

- ✓ **1Q 2024:** Collaboration with Merck KGaA, Darmstadt, Germany to discover two targeted protein degraders against critical oncogenic proteins
- ✓ **2024:** Deliver development candidate to collaboration partner

1. Cash, cash equivalents and marketable securities as of March 31, 2024 were \$299.2 million
Dexamethasone (dex); Colorectal cancer (CRC); Non-small cell lung cancer (NSCLC); Year-end (YE)

Cemsidomide (CFT7455)


Targeting IKZF1/3

Multiple Myeloma (MM)
& Non-Hodgkin's Lymphoma (NHL)


IKZF1/3 Degradation Drives Three Distinct Areas of Hematopoietic Biology; Degradating IKZF1/3 is a Validated Therapeutic Strategy in MM and NHL

IKZF1 / IKZF3 Transcription Factors


Drive MM and NHL Cell Growth and Survival



Activate Fully Differentiated T-cells



Regulate Hematopoietic Stem Cell Differentiation



Consequences of IKZF1/3 Degradation:

- MM and NHL Cell Death

- T-cell Activation


- On-target Neutropenia

Ikaros Family Zinc Finger proteins 1 and 3 (IKZF1/3); Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL)

Differentiated PK and Class-leading Catalytic Activity of Cemsidomide (CFT7455) Leads to Sustained Degradation Compared to Other Agents in this Class


Extended Plasma and Tumor Exposure

In Vivo Tumor PK



Leads to Optimized Degradation Kinetics


In Vivo Degradation Kinetics (48 hrs.)



mezigdomide (CC-92480); Ikaros family zinc finger protein (IKZF3); multiple myeloma (MM); pharmacodynamics (PD); pharmacokinetics (PK); once daily (QD)
Source: AACR 2022 presentation

Cemsidomide (CFT7455) Phase 1 Dose Escalation Trial's Goal is to Define the Safety Profile and Identify Signs of Anti-Tumor Activity in R/R MM and R/R NHL

Phase 1 Dose Escalation Trial



Endpoints

Primary:

- Safety and tolerability
- Determine the maximum tolerated doses

Secondary:

- Estimate anti-tumor activity
- Assess PK

Exploratory:

- Characterize target engagement
- Assess kinetics, depth, recovery and consistency of target engagement
- Assess immunomodulation

Pharmacokinetic (PK); Monday, Wednesday, Friday dosing (MWF); once daily (QD); Relapsed refractory multiple myeloma (R/R MM); Relapsed refractory non-Hodgkin's lymphoma (R/R NHL); Dexamethasone (Dex)

Schedule Adjustment Yielding Expected Results for Cemsidomide (CFT7455) as a Potential MM Therapy



Established Safety Profile and Dosing Schedule

- Cemsidomide (CFT7455) is well tolerated with no DLTs resulting in treatment discontinuations
- The 14 days on/14 days off schedule is optimal



Demonstrated Monotherapy Activity

- Anti-myeloma activity and immunomodulatory effects observed at well tolerated doses
- Opportunity in combination with novel MM agents for early-line patients and as a maintenance therapy option



Promising Responses with Cemsidomide (CFT7455) + Dexamethasone

- Multiple patients achieved IMWG responses at low doses with best responses in patients refractory to BCMA therapies
- Opportunity in combination with dexamethasone for multi-refractory patients




Cemsidomide (CFT7455) is a **potential treatment for multi-refractory MM patients** with the ability **to move into earlier lines** with numerous combination opportunities


Dose Limiting Toxicities (DLTs); Multiple myeloma (MM); B cell maturation antigen (BCMA); International Myeloma Working Group (IMWG)
Source: C4T data on file as 11/28/2023

Cemsidomide (CFT7455) Monotherapy Pharmacodynamics Consistent with 14 Days On/14 Days Off Modeling; Schedule is Sufficient for Neutrophil Recovery

Modeled PK/PD of 14 Days On/14 Days Off Schedule



Clinical PD of 14 Days On/14 Days Off Schedule



Daily dosing (QD); Pharmacokinetic (PK); Pharmacodynamic (PD); Monday, Wednesday, Friday dosing (MWF)
Source: C4T data on file as of 11/28/23

Cemsidomide (CFT7455) Monotherapy Data Support Opportunity for Combination with Novel MM Agents

Well Tolerated in Heavily Pre-Treated Patients with 14 Days on/14 Days off Schedule

Grade 3 or greater drug related effects were, as expected, neutropenia and other hematologic effects

No DLTs resulting in discontinuation across the entire monotherapy arm

Manageable neutropenia

Limited safety concerns outside of hematology, which is consistent with IKZF1/3 degraders

Evidence of Anti-Myeloma Monotherapy Activity


20 patients were efficacy evaluable and in total, achieved:

- 1 partial response
- 2 minimal responses
- 9 stable disease

All 4 patients at the maximum administered dose had stable disease or better

Dose limiting toxicity (DLT); Ikaros Family Zinc Finger Proteins 1 and 3 (IKZF1/3)
Source: C4T data on file as of 11/28/2023

Clinical Evidence of Immune T-cell Activation with Cemsidomide (CFT7455) Monotherapy



- 19 patient samples (PBMCs) analyzed by flow cytometry
- Aggregate data of 25 µg, 50 µg, and 75 µg MWF and QD

Supports potential of cemsidomide (CFT7455) as a maintenance therapy option and in combination with novel MM agents to improve efficacy:


- ✓ Cemsidomide (CFT7455) induces CD8+ T-cell activation by increasing effector memory T-cell subset
- ✓ T-cell activation is observed at well tolerated monotherapy clinical doses
- ✓ The clinical data consistent with the preclinical *in vitro* data reported for cemsidomide (CFT7455)

Peripheral Blood Mononuclear Cells (PBMCs); Daily dosing (QD); Monday, Wednesday, Friday Dosing Schedule (MWF); Multiple Myeloma (MM)
Source: C4T data on file as of 11/28/2023

Cemsidomide (CFT7455) Combined with Novel MM Agents Demonstrated Enhanced Immune Cell Lysis in Non-clinical Translational Models


Daratumumab (Anti-CD38) Combo

Antibody-Dependent Cell-Mediated Cytotoxicity Assay (ADCC)



Teclistamab (BCMA BiTE) Combo

T-cell Dependent Cellular Cytotoxicity Assay (TDCC)




C_{min} and C_{max} represent human plasma concentrations for a 50 μ g dose of CFT7455

Cemsidomide (CFT7455) + Dexamethasone Dose Escalation in R/R MM Continues to Progress

Phase 1: Dose Escalation + Dexamethasone 14 Days On/14 Days Off

KEY INCLUSION CRITERIA

- Adults with R/R MM, at least 3 prior lines that have included lenalidomide, pomalidomide, a proteasome inhibitor, a glucocorticoid, and an anti-CD38 monoclonal antibody
- Nonresponsive to or progressed within 60 days of prior therapy
- Measurable disease
- Adequate bone marrow function (ANC ≥ 1000 , Hgb ≥ 8.0 , platelets $\geq 75,000$)
- Creatinine clearance ≥ 40 mL/min
- ECOG ≤ 2



- 62.5 µg dose has been declared safe
- Enrolling patients at the next dose level
- Additional patients are enrolling in the 62.5 µg expansion cohort

Phase 2


Cohort
Expansion
N ≈ 30

Eastern Cooperative Oncology Group (ECOG); Monday, Wednesday, Friday dosing (MWF); Daily Dosing (QD); Relapsed/Refractory multiple myeloma (R/R MM); Absolute neutrophil count (ANC); Hemoglobin (Hgb); Dexamethasone (Dex); Dose level (DL)

*+Dex is dosed on days 1, 8, 15, and 22 and dose is reduced for older patients.

Cemsidomide (CFT7455) + Dexamethasone is Well Tolerated and Best Responses in Patients Refractory to BCMA Therapies

Anti-myeloma Activity:




Safety:

- Cemsidomide (CFT7455) + dexamethasone is well tolerated
- Consistent with the monotherapy safety signal
- No AEs have led to dose reductions, discontinuations or DLTs

Extramedullary Disease (EMD); T-Cell Engager (TCE); Daily Dosing (QD); One Weekly (QW); Monday, Wednesday, Friday Dosing (MWF); Dose Limiting Toxicity (DLTs); Dexamethasone (dex); B cell maturation antigen (BCMA); Adverse events (AEs)
Source: C4T data on file as of 11/28/2023

Cemsidomide (CFT7455) Profile Supports Multiple Opportunities across MM Landscape



* Other combination opportunities may include CAR-T, anti-SLAMF7, XPO1 inhibitors, FcRH5 BiTE, among others.

Bi-specific T-cell Engager (BiTE); Proteasome Inhibitors (PI); Multiple myeloma (MM); B cell maturation antigen (BCMA); G protein-coupled receptor, class C, group 5, member D (GPRC5D)

CFT1946

Targeting BRAF V600X

Melanoma, Colorectal (CRC)
& Non-Small Cell Lung Cancer (NSCLC)

CFT1946 has the Potential to Overcome Resistance Mechanisms Seen with Inhibition in BRAF V600X Cancers

Potential Advantages of BRAF V600X Degradation


- Specifically targets BRAF V600X mutation over wildtype BRAF
- Degradation prevents dimer formation and avoids paradoxical activation
- Addresses MAPK pathway resistance mechanisms from inhibitors
- Enables deep elimination of mutant BRAF signaling and creates durable responses through degrader molecule recycling and catalytic effect

Key Properties of CFT1946

- Orally bioavailable
- Potent and selective against BRAF V600X mutant targets while sparing wildtype activity
- Preclinical activity in settings of resistance to BRAF inhibitors
- Preclinical evidence of CNS activity


BRAF V600X CONDITION

Active BRAF V600X causes uncontrolled MAPK signaling, leading to tumorigenesis, tumor growth, and tumor maintenance




BRAF V600X Degradader Advantages Vary by Indication and May Require Combination

Melanoma & NSCLC Acquired Resistance










CFT1946 in combination with trametinib/MEK inhibitor may increase durability in the face of acquired resistance mechanisms

CRC Intrinsic Resistance



CFT1946 in combination with cetuximab may overcome resistance through blocking EGFR pathway

CFT1946 has the Potential to Address Multiple Tumor Types with BRAF V600X Mutations Where BRAF Inhibitors are Insufficient

	 BRAF V600X Mutation Rate	 2023 U.S. Incidence of BRAF V600X Patients ⁴	 Approved BRAF Inhibitors	 BRAF Inhibitor Regimen mPFS ⁵
 Melanoma	~35% ¹	~35,000	<ul style="list-style-type: none"> • Dabrafenib • Encorafenib • Vemurafenib <i>All used in combination with MEK inhibitors</i>	11.4 months (dabrafenib + trametinib in 1L+)
 Colorectal Cancer	5-10% ²	~11,000	<ul style="list-style-type: none"> • Encorafenib <i>Used in combination with cetuximab (anti-EGFR)</i>	4.2 months (encorafenib + cetuximab in 2L+)
 Non-Small Cell Lung Cancer	1-2% ³	~3,000	<ul style="list-style-type: none"> • Dabrafenib • Encorafenib <i>Both used in combination with MEK inhibitors</i>	15.2 months (dabrafenib + trametinib in 2L+)


Sources: 1. Owsley 2021 Exp Biol Med. 2. Paik 2011 J Clin Oncol. 3. Bylsma 2020 Cancer Med. 4. NCI SEER, consulting work done by Health Advances. 5. FDA Labels

CFT1946 is More Efficacious than SOC in CRC & NSCLC BRAF V600X Xenograft Models and in a Melanoma PDX BRAF Inhibitor Resistance Model

CRC

CFT1946 as a monotherapy and + cetuximab shows enhanced responses

CRC Cell-line (HT-29)




- Vehicle, PO/BID
- Cetuximab, 11 mg/kg IP/Q3D
- CFT1946, 10 mg/kg PO/BID
- CFT1946, 10 mg/kg PO/BID + Cetuximab, 11 mg/kg IP/Q3D
- Encorafenib, 35 mg/kg PO/QD
- Encorafenib, 35 mg/kg PO/QD + Cetuximab, 11 mg/kg IP/Q3D

NSCLC

CFT1946 as a monotherapy shows enhanced responses to dabrafenib + trametinib

NSCLC PDX Model




- Vehicle, PO/BID
- CFT1946, 10 mg/kg, PO/BID
- Dabrafenib, 100 mg/kg, PO/QD + Trametinib, 0.1 mg/kg, PO/BID
- Dabrafenib, 100 mg/kg, PO/QD

MELANOMA

CFT1946 + trametinib shows deep tumor regression

Melanoma PDX Model




- Vehicle, PO/BID
- Dabrafenib, 100 mg/kg, PO/QD + Trametinib, 0.1 mg/kg, PO/BID
- CFT1946, 10 mg/kg, PO/BID
- CFT1946, 10 mg/kg, PO/BID + Trametinib, 0.1 mg/kg, PO/BID


Oral administration (PO); Twice a day dosing (BID); Intraperitoneal injections (IP)
Source: C4T data on file as of 12/31/23

CFT1946 is Active in Preclinical Metastatic Melanoma CNS Models

CFT1946 Prolongs Survival Compared to Encorafenib (BRAF inhibitor) in CDX Model



CFT1946 Reduces CNS Tumor Burden in Metastatic Melanoma CNS Model




CFT1946 Phase 1/2 Dose Escalation Trial Continues to Progress

KEY INCLUSION CRITERIA¹

- ≥18 years of age
- Evidence of a BRAF V600X mutation obtained from tumor tissue or liquid biopsy
- Received ≥1 prior line of SoC therapy for unresectable locally advanced or metastatic disease, NSCLC, CRC, Melanoma, ATC or other BRAF V600X mutation-positive tumors
- No patient with CNS involvement (primary tumor or metastatic disease), except if clinically stable
- No patient with known malignancy other than trial indication that is progressing or has required treatment within the past 3 years, except for conditions that have undergone potentially curative therapy

Phase 1: Dose Escalation Monotherapy Arm for V600X Solid Tumors including CRC, Melanoma and NSCLC (Post BRAF Inhibitor)




Safety Combination Cohorts

- + trametinib for melanoma and NSCLC
- + cetuximab for CRC


Twice a day (BID); standard of care (SoC); Non-small cell lung cancer (NSCLC); Colorectal Cancer (CRC); Anaplastic thyroid cancer (ATC); Central nervous system (CNS); Dose Level (DL)
¹. NCT05668585. www.clinicaltrials.gov. Accessed January 9, 2024. ². Evaluating additional patients for pharmacodynamic evaluation pre- and post-drug exposure biopsies

At 80 mg, CFT1946 Degrades BRAF V600E in Melanoma Tissue and Demonstrates Rapid Decrease of BRAF V600E VAF in ctDNA

Patient 1: At 80 mg, CFT1946 Degrades BRAF V600E in Melanoma Tissue and Results in Reduced ERK Signaling



Patient 2: Rapid Decrease of BRAF V600E VAF in 15 Days of CFT1946 Treatment at 80 mg



Patient also demonstrated 7% decrease in tumor volume in correlation with the ctDNA data

Limit of Detection (LOD); Variant Allele Frequency (VAF); Circulating tumor DNA (ctDNA)
Source: C4T data on file as of 11/14/2023


CFT8919

Targeting EGFR L858R

Non-Small Cell Lung Cancer (NSCLC)

Potential for CFT8919 to Improve Outcomes for NSCLC Patients with EGFR L858R Mutations

Strong Rationale for an EGFR L858R Degradable



CFT8919 Key Properties

- Orally bioavailable
- Potent and selective against L858R, regardless of secondary mutations
- Allosteric binding



Market Size

- ~\$6B approved EGFR inhibitor market¹




Progress to Date

- Achieved FDA clearance of U.S. IND
- Beta received CTA clearance from China's NMPA

Non-small cell lung cancer (NSCLC); Tyrosine Kinase Inhibitor (TKI); Osimertinib (Osi); Investigational New Drug (IND); Clinical Trial Application (CTA)
Sources: Soria, J.C. et al. NEJM 378, 113–125 (2018); Sher, T. et al, Mayo Clin. Proc. 83, 355-367 (2008); 1. 2022 market size from EvaluatePharma.

CFT8919 is a Potent, Oral, Allosteric, Mutant-selective Degradator of EGFR L858R



- CFT8919 exploits **allosteric binding site**, close to L858R activating mutation
- Allosteric binding site avoids known resistance-causing mutations in **orthosteric binding site**
- Allosteric binders do not require covalent binding through C797S and do not compete with orthosteric binding

Allosteric binding avoids resistance mutations, wild-type activity, and is combinable with orthosteric inhibitors

2024 Milestones: Advancing High-potential Programs

Multiple Value Inflection Points over Next 12 Months with Sufficient Runway (into 2027¹) Beyond These Milestones

Cemsidomide (CFT7455) IKZF1/3

- **2H 2024:** Present updated data from Phase 1 dose escalation +dex trial in R/R MM
- **2H 2024:** Present data from Phase 1 dose escalation monotherapy trial in R/R NHL
- **By YE 2024:** Complete Phase 1 dose exploration in R/R MM and R/R NHL

CFT1946 BRAF V600X

- ✓ **2Q 2024:** Present preclinical data demonstrating differentiated activity in BRAF V600X melanoma, CRC, NSCLC, and brain metastasis models at AACR
- **2H 2024:** Present data from Phase 1 dose escalation trial in melanoma, CRC, NSCLC, and other BRAF V600X cancers

CFT8919 EGFR L858R

- **2024:** Support trial start-up activities related to Betta's Phase 1 dose escalation trial in China

Discovery

- ✓ **1Q 2024:** Collaboration with Merck KGaA, Darmstadt, Germany to discover two targeted protein degraders against critical oncogenic proteins
- ✓ **2024:** Deliver development candidate to collaboration partner

1. Cash, cash equivalents and marketable securities as of March 31, 2024 were \$299.2 million
Dexamethasone (dex); Colorectal cancer (CRC); Non-small cell lung cancer (NSCLC); Year-end (YE)